3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
Hidden Gem in China’s Fintech Market?
Yiren Digital is likely not a company you have heard of but in China it has been growing like a weed thanks to two primary fintech offerings: CreditTech and Wealth Management.
With the rapid growth of China’s fintech sector and the increasing demand for digital financial services, Yiren Digital has been putting up numbers that demand a closer look.
» Read more about: Hidden Gem in China’s Fintech Market? »
Read More
Oh, That Can’t Be Good
Usually, we talk about interesting stocks that may be on the cusp of growing revenues, profits or share price rapidly on a Tuesday but today we’re breaking from our regular programming to flag a major concern that could affect consumers. And because consumer spending is widely regarded to constitute about 70% of GDP, anything that affects it has a material impact on the broader stock market.
» Read more about: Oh, That Can’t Be Good »
Read More
Time to Buy Black Gold?
In spite of recent volatility, energy stocks have historically provided strong returns during periods of crude oil price recovery. With crude oil prices nearing the lower end of their range and a bullish shift in fundamentals, is now the time to begin long positions in the energy sector?
Crude oil is approaching the $70 per barrel mark,
» Read more about: Time to Buy Black Gold? »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
66% Upside In Asian Ride-sharing Stock?
Grab Holdings has evolved into Southeast Asia’s leading super-app with operations spanning ride-hailing, food/grocery delivery, and financial services.
Growth momentum has been strong, particularly since 2023 which was a pivotal year when Grab hit its first quarterly profit. That took place in Q4 2023 on $653 million revenue, up 30% year-on-year.
Under the hood,
» Read more about: 66% Upside In Asian Ride-sharing Stock? »
Read MoreThe Spotlight
AI Warren Buffett Is Finally Here
Before old Warren could hang up his gloves and call it a day at Berkshire Hathaway, a new wave of technology may well have taken his baton and started to run with it.
What do we mean? Well, it seems a new ETF has launched aimed at mimicking the moves of the top investors in the world.
» Read more about: AI Warren Buffett Is Finally Here »
Read MoreThe Daily
2 No-Brainer Warren Buffett Stocks to Buy Right Now
Warren Buffett’s holding company, Berkshire Hathaway, has done very well over the decades, posting average annual returns in excess of 20%. Much of this performance was generated from Berkshire’s publicly traded portfolio. And thanks to disclosure rules, we can dig into the regulatory filings and see which stocks Buffett likes best.
» Read more about: 2 No-Brainer Warren Buffett Stocks to Buy Right Now »